Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It also is setting up like a great tax sale candidate (like most everything else I own...).
Well, I still hold some WNFT and am prepared to wait it out. However, I expect things to take well into next year to resolve.
It sure was a dud. Their 3-way collaboration sounds to me like a college pot party.
Could be they are just dropping the Canadian listing to become exclusively US listed?
I believe that is a precondition for an uplist to NASDAQ and therefore I suspect this is a good thing.
More bravado and delays. Still no results.
We don't need signals, we need deals.
Dragging things out seems to be Calasse's entire motivation here. The longer things take to resolve in court the more Calasse has hurt Sharp.
I dug around after my post to you and I found this post on this board (dated 7/18/22)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169432301&txt2find=sesn
The author states that the Roche payment would be (up to?) $30M, or about .15 per share, if Roche initiates a Phase 3 trial on EBI-031 by the end of 2026. Assuming the share structure has not changed since then (?) that would imply a CVR value of up to .15, would which then need to be discounted in two ways - the payment is not certain and might not occur until 27 months from now.
I have not personally validated those numbers.
Do you have any feel for the value of the CVRs that SESN holders will get in addition to the share swap?
You got that right. A lot of this sounds better as Twiiter posturing than it does under the microscope of what actually makes it into an8K filed with the SEWC<
His departure was rather abrupt.
In this context I would assume EM would mean "Expert Market".
In other words, by failing to file financials MVNT would be at risk of being delisted from the otc at some point.
Thanks for the update. That makes sense. Unfortunately, there is no reason for Calasse to back off immediately - certainly there is no reason to do so until Sharp actually files his suit. Until then it is just threats.
My take is that Calasse will delay as long as he can. I have always thought that a lot of his motivation here might be "I don't really expect to win but by extending the legal process I can make it impossible for GS to do the deal he wants and therefore he loses too.
Imho neither pone of them gives a rat's ass about the rest of the people who hold shares in WNFT.
A short would probably attribute it to "amateur hour" at the beginning of the trading day and would not be worried about it at all.
Yes - up about 5% on low volume.
There is no date, and there is no source for "in process" status or information. It is a black box.
If Schrodinger's Cat were in this black box, it could have lived and died all of its nine lives and no one would know.
The Children of Israel eventually did get to the promised land, but they wandered around in the desert for 40 years before they got there...
It appears that Walbert was there only to (help) secure EU approval, and, with this accomplished, he is moving on. The fact that the resignation happened the same day as the EU approval, and that it was effective immediately, supports this thesis.
In general, directors' compensation is not tied to specific milestones, though it is possible.
There may also have been a "gentleman's agreement" to the effect of "help us get through EU approval" and then we'll go our separate ways.
The PR issued by ILUS on 9-9-22 was both specific and ambitious.
I am going to check back on 10/1 to see which of those predicted announcements actually were made in September and re-evaluate IOLUS based on how much of what they predicted actually became reality.
We all help the board in different ways. You are providing us, second-hand, the insights from you lawyer neighbor. I can't do that.
However, when it comes to snide comments from the peanut gallery, I'm all over it!
Yes - your biggest mistake was using "courts" and "speedy" in the same paragraph.
Question is with whom and about what...
It IS bad news. Things are more tangled up than we had previously hoped for. Even if Sharp wins across the board it is going to take TIME.
Anyone home here for NRDY? I am intrigued by the CEO's large recent purcahse.
I think you are expecting far more real--time automation than is actually the case here.
HOLy cOW!!!
I seem to be in a lot of shells where management couldn't find the ocean from the beach...
That's like the slightly pudgy girl who hangs out with obese friends to feel skinny.
Over a billion shares out is a lot on an absolute basis.
Damn! You're generous!
I think I am actually a distant cousin of yours. Can I hit you up for $50?
I too am a little surprised that the WNFT price has stabilized here and not dropped further in the absence of concrete news.
Probably. That 100K was a single trade, not a trend.
What language is that page in?
More likely, there could have been some preliminary discussions that ended in "ok, let's table this for a while and talk some more once Lupkynis gets EMA approval.
Big Pharma is generally willing to wait if that resolves uncertainty.
That would imply that ERT is already public, if they are going to "uplist". DO you know if ERT is public an, if so, the trading symbol and exchange for it?
That is true.
The recent PR referred to a prospective uplist of a subsidiary. Do you thin that is QIND or ERT? Seems to me that "uplist" ,eans an already-public company, so it would be QIND that they are referring to.
Correct - ALPP needs to make this easier.
There is no law or regulation that says that an institution can't buy an OTC stock.
That said, many institutions have internal bylaws that restrict the range of stocks they can buy. Some of those bylaws may be of the form "must be on Nasdaq or NYSE", but more likely they would be things like must have audited financials, must have a certain market cap, must have a given level of daily dollar volume, etc.
Institutions CAN buy otc stocks, but few otc stocks meet the criteria applied by most institutions to everything in their portfolio.
Why would they need to cover? They can stay short do units, common or warrants as long as they need to.
Any sign of life for NDTP is progress.
My assumption is quite different. I am guessing tht Dr. Otiko has these guys lined up but only pays them when he wants something communicated. In between those events, they don't return calls.